Navigation Links
Roche Diagnostics' HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
Date:10/29/2007

Roche HIV-1 monitoring technology used to validate results for Isentress

INDIANAPOLIS, Oct. 29 /PRNewswire/ -- Merck's new integrase inhibitor, Isentress, approved last week by the Food and Drug Administration, used Roche Diagnostics' COBAS(R) HIV-1 AMPLICOR viral load test during its clinical trials.

The new HIV drug, generically known as Raltegravir, is an HIV integrase inhibitor. Integrase inhibitors prevent replication of the virus by blocking insertion of HIV genetic material into human DNA. There are several other HIV integrase inhibitor drugs under development.

Isentress clinical trials researchers followed patients' progress by testing their viral loads with Roche's COBAS(R)HIV-1 AMPLICOR viral load test, which targets the gag region of the HIV virus genome, a different area from the integrase region where many new drugs in the HIV pipeline are being developed. Viral load testing, which quantifies the amount of HIV RNA in a patient's blood, is critical for evaluating response to therapy and as an aid to optimize patient treatment.

"With this new drug classification, it's important to choose an assay that can accurately detect viral load," said Dr. Bill Valenti, founding medical director and staff physician for the AIDS Community Health Center in Rochester, NY. "We've seen evidence of how easily HIV can mutate. If the targeted region mutates during viral load monitoring, the virus may become difficult to detect and quantitate, which may lead to inaccurate information on patients' responses to treatment."

Twenty-one natural polymorphisms and 42 resistance mutations have been identified so far in the integrase region of the HIV genome, according to a 2007 peer reviewed study published in Antiviral Therapy.

Roche's HIV-1 viral load test has been the predominant choice in HIV anti- retroviral clinical drug trials since 1996. Roche has provided research and expertise in comprehensive diagnostic tests for developing HIV anti-retroviral drugs.

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche

employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our U.S. website at http://www.roche-diagnostics.us.

All trademarks used or mentioned in this release are legally protected by law.

For further information please contact:

Lori McLaughlin

Corporate Communications

Roche Diagnostics Corporation, Indianapolis, Ind.

Phone: 317-521-3112

lori.mclaughlin@roche.com


'/>"/>
SOURCE Roche Diagnostics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
2. At the 2007 Alzheimers Association International Conference on the Prevention of Dementia - Neurochems U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)
3. New Advances in Gastric Diagnostics: Smaller is Better
4. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
5. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
6. Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference
7. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
8. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
9. SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193
10. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
11. Afid Therapeutics Obtains Positive Evaluation of its Triple Mode Viral Sequestration Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP announces ... purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ... October 31, 2016 (the "Class Period"). Zimmer Biomet ... markets orthopaedic reconstructive products, such as knee and hip reconstructive ... ...
(Date:1/13/2017)... , January 13, 2017 ... "Transfection Reagents and Equipment Market by Method (Biochemical ... Application (Biomedical, Protein Production), End User - Global ... studies the global market from 2016 to 2021. ... Billion by 2021 from USD 715.4 Million in ...
(Date:1/13/2017)... , January 13, 2017 The 2016 ... industry, with several states voting in favor of legalizing cannabis ... largest Cannabis market in the U.S. In addition, the state ... mark in annual cannabis products sales. The ArcView Group has ... which the legal cannabis sales in the U.S. last year ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic ... Journal , the official journal of The American Society for Aesthetic Plastic Surgery, ... The procedure is designed to correct drooping, retracted lower eyelids, which usually result ...
(Date:1/16/2017)... UT (PRWEB) , ... January 16, 2017 , ... One ... not only to treat, but to test for, as well. The money spent screening ... every year.(1) Doctors in the U.S. screen patients for cancer more than in any ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Executive Officer of the medical device company, effective immediately. , “This is perfect ... “Kevin has a strong track record in medical device market development and revenue ...
(Date:1/15/2017)... ... , ... In this role, Courtney will be responsible for developing new business ... friendly mark. This certification program was created by ASL and the nonprofit Asthma and ... suitable for the 60+ million people living in the U.S. with asthma and allergies. ...
(Date:1/15/2017)... ... ... is announcing the release of an updated version of their top selling clipper, the ... wide jaws that will accommodate nails up to 4mm in thickness . Nails like ... reinforced for extra strength when pressing down on dense nails which can be a hindrance ...
Breaking Medicine News(10 mins):